JoseBernardoVazquez-TanusMD

PubMed

• Evacetrapib and Cardiovascular Outcomes in High-Risk Vascular Disease.
  Lincoff AM, Nicholls SJ, Riesmeyer JS, Barter PJ, Brewer HB, Fox KAA, Gibson CM, Granger C, Menon V, Montalescot G, Rader D, Tall AR, McErlean E, Wolski K, Ruotolo G, ...> ;The New England journal of medicine.
• Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease.
  Ridker PM, Everett BM, Thuren T, MacFadyen JG, Chang WH, Ballantyne C, Fonseca F, Nicolau J, Koenig W, Anker SD, Kastelein JJP, Cornel JH, Pais P, Pella D, Genest J, C...> ;The New England journal of medicine. 2017-08-27
• Cardiovascular Efficacy and Safety of Bococizumab in High-Risk Patients.
  Ridker PM, Revkin J, Amarenco P, Brunell R, Curto M, Civeira F, Flather M, Glynn RJ, Gregoire J, Jukema JW, Karpov Y, Kastelein JJP, Koenig W, Lorenzatti A, Manga P, M...> ;The New England journal of medicine. 2017-03-17
• Aliskiren, Enalapril, or Aliskiren and Enalapril in Heart Failure.
  McMurray JJ, Krum H, Abraham WT, Dickstein K, Kober LV, Desai AS, Solomon SD, Greenlaw N, Ali MA, Chiang Y, Shao Q, Tarnesby G, Massie BM> ;N Engl J Med. 2016 Apr 21
• Phase 2 study of TAK-442, an oral factor Xa inhibitor, in patients following acute coronary syndrome.
  Goldstein S, Bates ER, Bhatt DL, Cao C, Holmes D, Kupfer S, Martinez F, Spaeder J, Weitz JI, Ye Z, Zannad F> ;Thromb Haemost. 2014 Jun
• Alogliptin after acute coronary syndrome in patients with type 2 diabetes.
  White WB, Cannon CP, Heller SR, Nissen SE, Bergenstal RM, Bakris GL, Perez AT, Fleck PR, Mehta CR, Kupfer S, Wilson C, Cushman WC, Zannad F> ;N Engl J Med. 2013 Oct 03
• Apixaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of the ARISTOTLE trial.
  Easton JD, Lopes RD, Bahit MC, Wojdyla DM, Granger CB, Wallentin L, Alings M, Goto S, Lewis BS, Rosenqvist M, Hanna M, Mohan P, Alexander JH, Diener HC> ;Lancet Neurol. 2012 Jun
• Vorapaxar in the secondary prevention of atherothrombotic events.
  Morrow DA, Braunwald E, Bonaca MP, Ameriso SF, Dalby AJ, Fish MP, Fox KA, Lipka LJ, Liu X, Nicolau JC, Ophuis AJ, Paolasso E, Scirica BM, Spinar J, Theroux P, Wiviott ...> ;N Engl J Med. 2012 Apr 12
• Thrombin-receptor antagonist vorapaxar in acute coronary syndromes.
  Tricoci P, Huang Z, Held C, Moliterno DJ, Armstrong PW, Van de Werf F, White HD, Aylward PE, Wallentin L, Chen E, Lokhnygina Y, Pei J, Leonardi S, Rorick TL, Kilian AM...> ;N Engl J Med. 2012 Jan 05
• Apixaban versus warfarin in patients with atrial fibrillation.
  Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, Al-Khalidi HR, Ansell J, Atar D, Avezum A, Bahit MC, Diaz R, Easton JD, Ezekowitz JA, Flaker G, Gar...> ;N Engl J Med. 2011 Sep 15
• Clopidogrel with or without omeprazole in coronary artery disease.
  Bhatt DL, Cryer BL, Contant CF, Cohen M, Lanas A, Schnitzer TJ, Shook TL, Lapuerta P, Goldsmith MA, Laine L, Scirica BM, Murphy SA, Cannon CP> ;N Engl J Med. 2010 Nov 11
• Saxagliptin added to a submaximal dose of sulphonylurea improves glycaemic control compared with uptitration of sulphonylurea in patients with type 2 diabetes: a rando...
  Chacra AR, Tan GH, Apanovitch A, Ravichandran S, List J, Chen R> ;Int J Clin Pract. 2009 Sep
• Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: a rand...
  Jadzinsky M, Pfutzner A, Paz-Pacheco E, Xu Z, Allen E, Chen R> ;Diabetes Obes Metab. 2009 Jun
• Join now to see all

Journal Articles

• Rosuvastatin to Prevent Events in Men and Women with Elevated C-Reactive Protein  
  Vazquez Tanus JB, New England Journal of Medicine, 1/20/2008
• Effects of Calcium Channel Blockers on Proteinuria in Patients with Diabetic Nephropathy  
  Vazquez Tanus JB, Journal of Clinical Hypertension, 1/1/2008
• Baseline Characteristics and Early Blood Pressure Control The Convince Trial  
  Vazquez Tanus JB, Journal Hypertension, 1/1/2001

Abstracts/Posters

• Permanent Pacemaker Infection. The Damas Hospital Experience.
  Vazquez Tanus JB, Journal Science – Ciencia, Fall; Regional Meeting of The American College of Physician, San Juan, Puerto Rico, 1/1/1988
• Sub lingual Captopril in Hypertensive Emergencies. Prospective clinical study conducted in Damas & Yauco area hospitals.
  Vazquez Tanus JB, Boletin de Asociacion Medica; Puerto Rican Congress of Cardiology, 1/1/1987

Lectures

• Sublingual Nifedipine in Hypertensive Emergencies. Prospective Clinical study conducted in Damas & Yauco Area hospitals. 
• Echocardiography study of pericardial effusion with hemodynamic compromise signs. Retrospective study of admitted cases to Damas Hospital, with diastolic collapse. 
• Hypertension treatment. 
• Altering clinical course of Heart Failure 
• Arterial wall; the new target for hypertension. 
• Beyond symptom relieve, slowing the progression of heart failure. 
• Cholesterol lowering in the patient with coronary heart disease 
• Diabetes & the impact of risk factors clustering. 
• Diabetes management & pharmacologic therapy 
• Hyperlipidemia and cardiovascular risk factors. 
• Hyperlipidemia diagnoses and treatment. 
• Hypertension, rennin Blockers ACE receptor blockers. 
• Inflammation angiogenesis and ACE inhibition 
• Management of lipid disorder. 
• Managing Hypertension & Angina 
• Managing Lipids and risk reduction. 
• Non Valvular Atrial fibrillation, thrombotic risk beyond the arrhythmia 
• Pericardial disease. 
• Platelets glycoprotein II-B/IIIA inhibitors new device 
• Risk reduction in heart disease. 
• T-Channels in hypertension. 
• Join now to see all